Live Breaking News & Updates on Baropace Michael Burnam Nonpharmacologic Hypertension Medical Device Company Resistant Heart Failure Preserved Ejection Fraction Hfpef Firstinhuman Fih Clinical Trial Cardiac Pacemaker Relievehfpefii Multicenter Doubleblind Pressurepace Programming Adjustments Modified Bruce Treadmill Protocol Fibrillation Incidences

Stay updated with breaking news from Baropace michael burnam nonpharmacologic hypertension medical device company resistant heart failure preserved ejection fraction hfpef firstinhuman fih clinical trial cardiac pacemaker relievehfpefii multicenter doubleblind pressurepace programming adjustments modified bruce treadmill protocol fibrillation incidences. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

BaroPace Inc. Announced First Patient Enrolled in NonPharmacologic Hypertension and Heart Failure Treatment Trial

BaroPace Inc. a medical device company focused on the development of PressurePace a realtime physiologic control software and hardware to regulate cardiac pacemakers to treat resistant hypertension and heart failure with preserved ejection fraction HFpEF today announced that the first patient has been enrolled in the Companys FirstinHuman FIH clinical trial RelieveHFpEFII. ....

United States , Jessica Burnam , Aboutbaropace Inc , Baropace Inc , Space Inc , Minnesota Living , Heart Failure , Michael Burnam , Media Contact , Baropace Michael Burnam Nonpharmacologic Hypertension Medical Device Company Resistant Heart Failure Preserved Ejection Fraction Hfpef Firstinhuman Fih Clinical Trial Cardiac Pacemaker Relievehfpefii Multicenter Doubleblind Pressurepace Programming Adjustments Modified Bruce Treadmill Protocol Fibrillation Incidences ,